This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Opdivo
  • /
  • Study of Nivolumab in Subjects With Classical Hodg...
Clinical trial

Study of Nivolumab in Subjects With Classical Hodgkin's Lymphoma (Registrational) (CheckMate 205)

Read time: 1 mins
Last updated:30th Jun 2014

The purpose of this study is to evaluate the efficacy and safety of Nivolumab in previously treated (cohorts, A, B & C) or newly diagnosed (cohort D) classical Hodgkin Lymphoma subjects.

Study Type: Interventional
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Non-Comparative, Multi-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in Classical Hodgkin Lymphoma (cHL) Subjects
Estimated Enrollment: 294
Study Start Date: July 2014
Estimated Study Completion Date: December 2018
Estimated Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)

- Experimental:
Nivolumab (Cohort A, B, C and D)

Category Value
Study start date 2014-07-01

View full details